US Bancorp’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

US Bancorp’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,500	Closed	-$5K	–	3760
2017 Q2	$5K	Hold	1,500	–	–	﹤0.01%	3258
2017 Q1	$14K	Hold	1,500	–	–	﹤0.01%	2956
2016 Q4	$12K	Hold	1,500	–	–	﹤0.01%	2994
2016 Q3	$17K	Hold	1,500	–	–	﹤0.01%	2879
2016 Q2	$18K	Hold	1,500	–	–	﹤0.01%	2850
2016 Q1	$15K	Sell	1,500 -3,587	-71%	-$42.1K	﹤0.01%	2885
2015 Q4	$115K	Buy	5,087 +73	+1%	+$1.5K	﹤0.01%	1992
2015 Q3	$83K	Buy	5,014 +2,153	+75%	+$43.2K	﹤0.01%	2186
2015 Q2	$64K	Buy	2,861 +1,637	+134%	+$40.4K	﹤0.01%	2408
2015 Q1	$32K	Buy	+1,224	New	+$31K	﹤0.01%	2755

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

US Bancorp's OMED Position: Q3 2017 in Review

US Bancorp sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2017, closing a stake of 1,500 shares — an estimated $5K sold.

US Bancorp first reported a position in OMED in Q1 2015 and held it in 10 quarters. The position peaked at $115K in Q4 2015. 58 funds tracked by Wall St. Rank hold OMED as of Q3 2017.

US Bancorp reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
US Bancorp sold 1,500 OncoMed Pharmaceuticals, Inc. shares in Q3 2017, an estimated $5K.
US Bancorp first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2015 and held it in 10 quarters.
US Bancorp's OncoMed Pharmaceuticals, Inc. position peaked at $115K in Q4 2015.
58 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2017.

Based on US Bancorp's 13F filing for Q3 2017, filed 13 Nov 2017.